<DOC>
	<DOCNO>NCT00315133</DOCNO>
	<brief_summary>The study evaluate effect inactivation immune system chemotherapy immunotherapy infusion bone marrow stem cell early onset type 1 diabetes mellitus . We hypothesize reprograming immune system stop immune aggression insulin produce cell allow regeneration thus decrease eliminate need exogenous insulin .</brief_summary>
	<brief_title>Safety Efficacy Study Autologous Stem Cell Transplantation Early Onset Type I Diabetes Mellitus</brief_title>
	<detailed_description>Patients 12 35 year old type I diabetes mellitus prove anti-pancreatic beta cell antibody recently diagnose ( less 6 week ) include study . Peripheral blood hematopoietic stem cell mobilize bone marrow patient cyclophosphamide plus G-CSF ( granulocyte-colony stimulating factor ) , collect leukapheresis cryopreserved . After 2-3 week , high dose immunosuppression give ( cyclophosphamide 200 mg/kg plus rabbit antithymocyte globulin 4.5 mg/kg ) stem cell thaw injected intravenously . This procedure perform isolated room Bone Marrow Transplantation Unit School Medicine Ribeirão Preto , University São Paulo , Brazil . Patients discharge hospital engraftment closely follow 2 month transplantation ( least weekly outpatient visit ) continue followup 5 year transplantation . Clinical , hematological , metabolical immunological evaluation perform analyse effect transplant disease hematopoetic immunologic system body . Patients fit inclusion criterion agree perform transplantation control group follow parallel transplant patient .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<criteria>Type 1 diabetes mellitus diagnose clinical/metabolic parameter positive antiGAD antibody Less 12 week diagnosis Previous diabetic ketoacidosis Pregnancy Severe psychiatric disorder Severe organic impairment ( renal , hepatic , cardiac , pulmonary ) Active infectious disease Previous present neoplastic disease</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Diabetes mellitus</keyword>
	<keyword>Stem cell</keyword>
	<keyword>Autologous stem cell transplantation</keyword>
	<keyword>Autoimmune disease</keyword>
</DOC>